Zafgen Inc (NASDAQ:ZFGN) has been assigned an average rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $17.33.
Several analysts have recently issued reports on ZFGN shares. Wedbush started coverage on Zafgen in a report on Thursday, August 2nd. They set an “outperform” rating and a $14.00 price objective on the stock. Piper Jaffray Companies started coverage on Zafgen in a report on Tuesday, July 3rd. They set an “overweight” rating and a $18.00 price objective on the stock. BidaskClub raised Zafgen from a “hold” rating to a “buy” rating in a report on Tuesday, July 3rd. Cowen reaffirmed a “hold” rating on shares of Zafgen in a report on Monday, June 25th. Finally, Zacks Investment Research cut Zafgen from a “hold” rating to a “sell” rating in a report on Thursday, June 21st.
In other news, insider Thomas E. Hughes sold 32,000 shares of the company’s stock in a transaction that occurred on Thursday, June 28th. The stock was sold at an average price of $10.00, for a total transaction of $320,000.00. Following the sale, the insider now directly owns 125,247 shares of the company’s stock, valued at approximately $1,252,470. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 23.70% of the stock is owned by corporate insiders.
Large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its holdings in Zafgen by 25.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 864,972 shares of the biopharmaceutical company’s stock valued at $6,444,000 after buying an additional 174,482 shares during the period. AlpInvest Partners B.V. purchased a new stake in Zafgen during the 2nd quarter valued at $1,436,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Zafgen during the 2nd quarter valued at $110,000. DAFNA Capital Management LLC purchased a new stake in Zafgen during the 2nd quarter valued at $1,671,000. Finally, Barclays PLC raised its holdings in Zafgen by 139,086.7% during the 1st quarter. Barclays PLC now owns 20,878 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 20,863 shares during the period. Institutional investors own 72.58% of the company’s stock.
Shares of ZFGN traded down $0.56 during mid-day trading on Friday, hitting $10.12. 150,406 shares of the stock were exchanged, compared to its average volume of 226,715. The stock has a market capitalization of $384.61 million, a price-to-earnings ratio of -5.33 and a beta of -0.62. Zafgen has a 52-week low of $3.24 and a 52-week high of $11.36. The company has a debt-to-equity ratio of 0.36, a current ratio of 8.42 and a quick ratio of 8.42.
Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.02. sell-side analysts expect that Zafgen will post -2.05 earnings per share for the current year.
Zafgen Company Profile
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Recommended Story: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.